

Supplementary Table 1

<u>Agent Class</u>	<u>Agent Name</u>	<u>Company</u>	<u>Clinical Trial Phase</u>	<u>Reference</u> ^a
<i>Pan-class I PI3K</i>	GDC-0941	Genentech	1, 2	1
	NVP-BKM120	Novartis	1, 2	2
	XL147 (SAR245408)	Sanofi	1, 2	3
	PX-866	Oncothyreon	1, 2	4
	BAY806946	Bayer	1, 2	5
	CH5132799	Chugai	1	6
<i>Isoform-selective PI3K (target)</i>	NVP-BYL719 (p110 α)	Novartis	1, 2	7
	MLN1117 (p110 α)	Millennium	1	8
	AZD8186 (p110 β)	Astra-Zeneca	1	doi: 10.1158/1538-7445. AM2013-3264
	SAR260301 (p110 β)	Sanofi	1	doi: 10.1158/1538-7445. AM2013-3258
	GSK2636771 (p110 β)	Glaxo Smith Kline	1	
	GS-1101 (p110 δ)	Gilead	1, 2, 3	9
	AMG 319 (p110 δ)	Amgen	1	Not published
	GS-9820	Gilead	1,2	Not published
	IPI-145 (p110 δ/γ)	Infinity	1, 2	Not published
	GDC-0032 (p110 $\alpha/\delta/\gamma$)	Genentech	1	10
<i>PI3K (unspecified)</i>	GDC-0084	Genentech	1	Not published
<i>Rapalog</i>	RAD001 (everolimus)	Novartis	approved	
	CCI-779 (temsirolimus)	Wyeth/Pfizer	approved	
	AP23573 (deforolimus)	ARIAD/Merck	approved	
<i>mTOR kinase inhibitor</i>	MLN0128	Millennium	1	11
	AZD2014	Astra-Zeneca	1, 2	12
	OSI-027	OSI/Estellas	1	13
	CC-223	CelGene	1, 2	Not published
<i>panPI3K/mTOR inhibitor</i>	NVP-BEZ235	Novartis	1, 2	14
	NVP-BGT226	Novartis	1,2	15

SUPPLEMENTARY INFORMATION

	XL765 (SAR245409)	Sanofi	1, 2	16
	GDC-0980	Genentech	1, 2	17
<i>AKT inhibitor</i>	MK-2206	Merck	1, 2	18
	GDC-0068	Genentech	1, 2	19
	GSK2141795	Glaxo Smith Kline	1, 2	20
	GSK2110183	Glaxo Smith Kline	1	Not published
	AZD5363	Astra-Zeneca	1	21

^a References listed [on next page](#)

Supplementary references

- Folkes, A.J. et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. *J Med Chem* **51**, 5522-32 (2008).
- Brachmann, S.M. et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. *Mol Cancer Ther* **11**, 1747-57 (2012).
- Chakrabarty, A. et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. *Cancer Res* **73**, 1190-200 (2013).
- Ihle, N.T. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. *Mol Cancer Ther* **3**, 763-772 (2004).
- Liu, N. et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 α and p110 δ activities in tumor cell lines and xenograft models. *Mol Cancer Ther* **12**, 2319-30 (2013).
- Ohwada, J. et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. *Bioorg Med Chem Lett* **21**, 1767-72 (2011).
- Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. *Bioorg Med Chem Lett* (2013).
- Jessen, K. et al. A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. *Mol Cancer Ther* **10**, Abstract A171 (2011).
- Macias-Perez, I.M. & Flinn, I.W. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. *Curr Hematol Malig Rep* **8**, 22-7 (2013).
- Ndubaku, C.O. et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. *J Med Chem* **56**, 4597-610 (2013).
- Hsieh, A.C. et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature* **485**, 55-61 (2012).
- Pike, K.G. et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. *Bioorg Med Chem Lett* **23**, 1212-6 (2013).
- Bhagwat, S.V. et al. Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin. *Mol Cancer Ther* (2011).
- Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. *Mol Cancer Ther* **7**, 1851-63 (2008).
- Chang, K.Y. et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. *Clin Cancer Res* **17**, 7116-26 (2011).
- Prasad, G. et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. *Neuro Oncol* (2011).
- Wallin, J.J. et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. *Mol Cancer Ther* **10**, 2426-36 (2011).
- Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. *Mol Cancer Ther* **9**, 1956-67 (2010).
- Blake, J.F. et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. *J Med Chem* **55**, 8110-27 (2012).
- Pachl, F. et al. Characterization of a chemical affinity probe targeting Akt kinases. *J Proteome Res* **12**, 3792-800 (2013).
- Davies, B.R. et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. *Mol Cancer Ther* **11**, 873-87 (2012).